Intrinsic Value of S&P & Nasdaq Contact Us

Becton, Dickinson and Company BDX NYSE

NYSE • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score
56/100
2/7 Pass
SharesGrow Intrinsic Value
$318.86
+104.8%
Analyst Price Target
$193.80
+24.4%

Becton, Dickinson and Company (BDX) generated $3.43B in operating cash flow for fiscal year 2025. After capital expenditures of $760M, free cash flow was $2.67B.

Free cash flow margin was 12.2% of revenue. Cash conversion ratio was 2.04x, indicating earnings are backed by cash.

The company returned $1.2B in dividends and $1B in share buybacks to shareholders during the period.

Criteria supported by this page:

  • HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
  • MOAT (73/100, Pass) — $2.67B (12.2% FCF margin) supports a durable competitive advantage
  • INCOME (45/100) — Cash conversion ratio was 2.04x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 56/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
56/100
SG Score
View full scorecard →
VALUE
36/100
Price-to-Earnings & upside
→ Valuation
~
FUTURE
46/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
~
HEALTH
50/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
73/100
Proven by this page
~
GROWTH
40/100
→ Income
~
INCOME
45/100
→ Income
Becton, Dickinson and Company Cash Flow History
Metric TTM FY2025 FY2024 FY2023 FY2022
Operating Cash Flow $3.39B$3.43B$3.8B$2.99B$2.63B
Capital Expenditure $-763M$-760M$-725M$-874M$-973M
Free Cash Flow $2.63B$2.67B$3.07B$2.12B$1.66B
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message